A Phase 1b/2a Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate Efficacy, Safety, Tolerability and the Pharmacokinetics of GL0034 (Utreglutide) in the Treatment of Non-alcoholic Fatty Liver Disease
Latest Information Update: 22 Jan 2026
At a glance
- Drugs Utreglutide (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors Sun Pharmaceutical Industries
Most Recent Events
- 22 Jan 2026 New trial record